Silence Therapeutics Plc ADR (SLN)

Mar 5, 2025, 8:00 AM EST - 4 days ago

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

Feb 28, 2025, 11:59 AM EST - 8 days ago

Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:30 AM EST - 10 days ago

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Feb 13, 2025, 8:00 AM EST - 24 days ago

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

Dec 18, 2024, 7:46 AM EST - 2 months ago

Top 3 Health Care Stocks That May Explode In Q4

MODV OLMA

Dec 9, 2024, 7:30 AM EST - 3 months ago

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

Nov 26, 2024, 8:00 AM EST - 3 months ago

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 3:34 PM EST - 3 months ago

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

Nov 19, 2024, 7:52 AM EST - 3 months ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

AMRN TERN

Nov 18, 2024, 2:30 PM EST - 3 months ago

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Nov 14, 2024, 8:00 AM EST - 4 months ago

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 13, 2024, 8:00 AM EST - 4 months ago

Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Sep 8, 2024, 9:13 AM EDT - 6 months ago

Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy'

Sep 5, 2024, 2:18 PM EDT - 6 months ago

Silence: Additional siRNA Drug Data Leads To Next Stages Of Development

Aug 27, 2024, 8:00 AM EDT - 6 months ago

Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

Aug 15, 2024, 7:30 AM EDT - 7 months ago

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jun 27, 2024, 7:30 AM EDT - 9 months ago

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Jun 24, 2024, 8:30 AM EDT - 9 months ago

Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration

Jun 21, 2024, 2:31 PM EDT - 9 months ago

Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results

Jun 20, 2024, 7:30 AM EDT - 9 months ago

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

May 30, 2024, 8:30 AM EDT - 10 months ago

Silence Therapeutics to Present at Jefferies Global Healthcare Conference

May 16, 2024, 8:30 AM EDT - 10 months ago

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

Apr 30, 2024, 8:30 AM EDT - 11 months ago

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Apr 29, 2024, 8:30 AM EDT - 11 months ago

Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

Apr 8, 2024, 11:48 AM EDT - 11 months ago

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Mar 13, 2024, 10:01 AM EDT - 1 year ago

Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 7:05 AM EDT - 1 year ago

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Mar 13, 2024, 7:00 AM EDT - 1 year ago

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Feb 28, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

Feb 24, 2024, 8:53 PM EST - 1 year ago

Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look

Feb 23, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Feb 5, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

Jan 31, 2024, 7:00 AM EST - 1 year ago

Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Dec 1, 2023, 7:00 AM EST - 1 year ago

Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments

Nov 14, 2023, 7:00 AM EST - 1 year ago

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

Nov 8, 2023, 7:00 AM EST - 1 year ago

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Nov 1, 2023, 7:00 AM EDT - 1 year ago

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Sep 26, 2023, 7:00 AM EDT - 1 year ago

Silence Therapeutics to Participate in Fireside Chat at Chardan's 7th Annual Genetic Medicines Conference

Sep 6, 2023, 7:00 AM EDT - 1 year ago

Silence Therapeutics to Participate in September Investor Conferences

Aug 16, 2023, 7:00 AM EDT - 1 year ago

Silence Therapeutics Reports Second Quarter 2023 Results

Jul 14, 2023, 7:15 PM EDT - 1 year ago

Silence Therapeutics: No Reason For It To Fall So Much

Jul 11, 2023, 7:00 AM EDT - 1 year ago

Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration

May 31, 2023, 7:00 AM EDT - 1 year ago

Silence Therapeutics to Present at the Jefferies Healthcare Conference

May 16, 2023, 4:00 PM EDT - 1 year ago

Silence Therapeutics Reports First Quarter 2023 Results

May 4, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration

May 1, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Apr 25, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference

Apr 4, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera

Mar 29, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics to Present at Guggenheim's Genomic Medicines and Rare Disease Days

Mar 28, 2023, 7:05 AM EDT - 2 years ago

Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development